Cancer Genetics (CGIX) Tops Q2 EPS by 5c

Cancer Genetics (NASDAQ: CGIX) reported Q2 EPS of ($0.28), $0.05 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $7 million versus the consensus estimate of $6.5 million.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c